Principal Financial Group Inc. Sells 21,919 Shares of Elanco Animal Health Incorporated (NYSE:ELAN)

Principal Financial Group Inc. reduced its position in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 41.0% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 31,489 shares of the company’s stock after selling 21,919 shares during the quarter. Principal Financial Group Inc.’s holdings in Elanco Animal Health were worth $463,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Benjamin F. Edwards & Company Inc. lifted its holdings in shares of Elanco Animal Health by 337.7% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 1,764 shares of the company’s stock worth $26,000 after purchasing an additional 1,361 shares in the last quarter. ORG Wealth Partners LLC acquired a new position in Elanco Animal Health during the third quarter worth $29,000. AM Squared Ltd bought a new position in shares of Elanco Animal Health in the third quarter valued at $34,000. Wilmington Savings Fund Society FSB acquired a new position in shares of Elanco Animal Health during the third quarter valued at about $35,000. Finally, Quarry LP bought a new stake in shares of Elanco Animal Health during the second quarter worth about $40,000. Institutional investors own 97.48% of the company’s stock.

Analyst Upgrades and Downgrades

ELAN has been the topic of a number of recent research reports. Leerink Partners began coverage on Elanco Animal Health in a report on Monday, December 2nd. They issued a “market perform” rating and a $14.00 target price on the stock. Leerink Partnrs upgraded Elanco Animal Health to a “hold” rating in a research note on Monday, December 2nd. Stifel Nicolaus reaffirmed a “buy” rating and set a $20.00 price objective on shares of Elanco Animal Health in a report on Thursday, September 19th. Barclays increased their target price on shares of Elanco Animal Health from $19.00 to $20.00 and gave the company an “overweight” rating in a report on Friday, November 8th. Finally, UBS Group began coverage on shares of Elanco Animal Health in a report on Monday, December 9th. They set a “buy” rating and a $18.00 price target on the stock. One analyst has rated the stock with a sell rating, four have given a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $16.71.

Elanco Animal Health Stock Down 0.6 %

Shares of NYSE ELAN opened at $11.98 on Monday. The stock has a market capitalization of $5.92 billion, a P/E ratio of 29.95, a PEG ratio of 2.03 and a beta of 1.41. Elanco Animal Health Incorporated has a one year low of $11.40 and a one year high of $18.80. The firm’s 50 day simple moving average is $12.76 and its two-hundred day simple moving average is $13.65. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.55 and a quick ratio of 1.31.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings data on Thursday, November 7th. The company reported $0.13 earnings per share for the quarter, beating the consensus estimate of $0.12 by $0.01. Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The firm had revenue of $1.03 billion during the quarter, compared to the consensus estimate of $1.04 billion. During the same quarter in the previous year, the company posted $0.18 earnings per share. The business’s revenue was down 3.6% on a year-over-year basis. As a group, analysts expect that Elanco Animal Health Incorporated will post 0.92 EPS for the current fiscal year.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.